Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VK combines Zen with the Pulse recommendation system

3/14/23 VKCO

MTS Ready to Sell Viva-MTS Subsidiary in Armenia, Subject to Good Assessment of the Asset

3/14/23 MTSS

Dmitry Klenow exited the capital of Detsky Mir

3/13/23 DSKY

Zynex reported revenue growth of 21.4% in 2022

3/13/23 ZYXI

The Applied Materials announced a quarterly dividend

3/13/23 AMAT

Pfizer buys biotech company Seagen

3/13/23 PFE

Pfizer buys Seagen for $229 per share

3/13/23 SGEN

Magadanenergo reported for 2022 according to RAS

3/13/23 MAGE

RESC reported for 2022 according to RAS

3/13/23 RZSB

Sanofi buys pharma company Provention Bio

3/13/23 SNY